A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

NCT00000691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

NIH

Sponsor class

Conditions

Cytomegalovirus Retinitis
HIV Infections

Interventions

DRUG: Foscarnet sodium

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)